Navigation Links
Bioness Inc. Announces Completion of Enrollment in Its FASTEST L300 Study
Date:10/4/2011

VALENCIA, Calif., Oct. 4, 2011 /PRNewswire/ -- Bioness Inc. today announced that the company has completed the initial enrollment phase of the FASTEST study to further examine the impact of its NESS L300 wireless neurostimulation technology on individuals with foot drop as a result of stroke. The FASTEST study aims to demonstrate the superiority of the NESS L300® Foot Drop System over standard therapy with an ankle-foot orthosis (AFO), and has enrolled 176 patients at 11 U.S. centers.

The NESS L300 provides an electrical stimulus to the muscles of the lower leg in order to help lift the foot up while walking. The system was cleared by the FDA in 2006, and received CE Mark from the European Union in 2007. The NESS L300 is currently available in rehabilitation centers across the country, and for home use by individuals suffering from foot drop as the result of neurological conditions including stroke, multiple sclerosis (MS), traumatic brain injury (TBI) and spinal cord injury (SCI).

Patients enrolled in the study receive rehabilitation therapy with either the NESS L300 or an AFO, and will be followed for six months and evaluated based on gait function, stroke-specific quality of life and safety.

"We are pleased to have reached this milestone and are greatly appreciative of the commitment and support of our clinical partners in reaching this goal," said Thomas Fogarty, President of Bioness Inc. "We look forward to seeing the outcome of this study and further quantifying the impact of this important technology for those who need it most."

About Bioness Inc.

Bioness provides neuromodulation technologies that help improve lives and restore function for those living with neurological deficits and peripheral pain. The Company markets innovative neuromodulation products that help individuals with central nervous system disorders such as stroke, multiple sclerosis, spinal cord injury and traumatic brain injury regain movement in affected limbs. The NESS L300® Foot Drop System and NESS H200® Hand Rehabilitation System, NESS L300® Plus System and NESS H200® Wireless Hand Rehabilitation System are cleared for use by the Food and Drug Administration and are designed to help patients achieve new levels of physical independence and productivity.

Individual results vary. Consult with a qualified physician to find out if these products are right for you. Additional information about Bioness can be found at www.bioness.com.  

Media Contact:
Wendy Ryan/Courtney Conery
Schwartz MSL
781-684-0770
bioness@schwartzmsl.com


'/>"/>
SOURCE Bioness Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Bioness Inc. Receives FDA Clearance of Its NESS L300 Plus System
2. Bioness Inc Announces Availability of L300 Plus System
3. Bioness Inc. Receives FDA Clearance and CE Mark for Its NESS H200 Wireless System for Hand Paralysis as a Result of Stroke and Other Central Nervous System Disorders
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... DIEGO , Oct. 12, 2017 AVACEN ... recognized the company with their  2017 New Product Innovation Award ... based on extensive primary and secondary medical device market research ... Medical, through its first-to-market OTC, drug-free pain relief product, the ... unique approach to treating fibromyalgia widespread pain. ...
(Date:10/12/2017)... , Oct. 12, 2017 West Pharmaceutical ... innovative solutions for injectable drug administration, today announced that ... market opens on Thursday, October 26, 2017, and will ... and business expectations at 9:00 a.m. Eastern Time. To ... 253-336-8738 (International). The conference ID is 94093362. ...
(Date:10/11/2017)... , Oct. 11, 2017  Caris Life Sciences ... on fulfilling the promise of precision medicine, today announced ... joined Caris, Precision Oncology Alliance™ (POA) as its 17 ... centers, the St. Jude Crosson Cancer Institute will help ... the use of tumor profiling, making cancer treatment more ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Apple ... care services, staged a mock evacuation of the facility as part of a disaster ... Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well as the ...
(Date:10/13/2017)... ... 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of ... popular and least understood books in the Holy Scriptures, Revelation. The Book of Revelation ... scholars for centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins ...
(Date:10/12/2017)... ... October 12, 2017 , ... First ... compliance program management, will showcase a range of technology and learning solutions at ... (NCAL) Convention and Expo to be held October 14–18, 2017 at the Mandalay ...
(Date:10/12/2017)... Bethesda, MD (PRWEB) , ... October 12, 2017 , ... ... Award of Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s ... 4 – 8. , In honor of Morris F. Collen, a pioneer in the ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at ... for the 49th Congress of the International Society of Paediatric Oncology (SIOP) ... Center for Cancer and Blood Disorders at Children’s National, and Stephen P. ...
Breaking Medicine News(10 mins):